Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$13.85

-0.55 (-3.82%)

05:35
04/09/18
04/09
05:35
04/09/18
05:35

Iovance named as defendant in stockholder derivative complaint

Iovance Biotherapeutics disclosed late Friday that on March 28, a purported stockholder derivative complaint was filed derivatively by plaintiff Nazeer Khaleeluddin against the company and certain of the company's current and former officers and directors in the U.S. District Court for the District of Delaware. The complaint alleges, among other things, violations of securities law, breach of fiduciary duty, aiding and abetting, waste of corporate assets, and unjust enrichment. The complaint is based on claims arising from the SEC's investigation into stock promotions and the company's April 10, 2017 settlement thereof. Iovance stated, "The Company intends to vigorously defend against the foregoing complaint. Based on the very early stage of the litigation, it is not possible to estimate the amount or range of possible loss that might result from an adverse judgment or a settlement of the matter."

IOVA Iovance Biotherapeutics
$13.85

-0.55 (-3.82%)

02/09/18
JEFF
02/09/18
NO CHANGE
Target $31
JEFF
Buy
Iovance Biotherapeutics price target raised to $31 from $11 at Jefferies
Jefferies analyst Biren Amin raised his price target for Iovance Biotherapeutics to $31 saying the FDA is likely to agree to the company's proposal to run a Phase II trial in refractory melanoma using less stringent endpoints such as response rates and duration of response versus overall survival. He believes LN-144 could provide a "compelling option for patients refractory to IO therapies." The analyst now includes estimates for the head and neck cancer indication where he added risk-adjusted peak U.S. revenue of $334M citing "early encouraging data." Amin keeps a Buy rating on Iovance.
02/23/18
RILY
02/23/18
DOWNGRADE
Target $18.5
RILY
Neutral
Iovance downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Madhu Kumar downgraded Iovance Biotherapeutics to Neutral while raising his price target for the shares to $18.50 from $18. The downgrade follows the recent move higher in the shares.
03/13/18
JEFF
03/13/18
NO CHANGE
Target $31
JEFF
Buy
Iovance data updates in 2018 should drive further upside, says Jefferies
Iovance Biotherapeutics last night provided an update on four ongoing clinical programs and its regulatory strategy for the melanoma program, Jefferies analyst Biren Amin writes in a post-earnings research note. Iovance continues to have an ongoing FDA dialogue and it is possible the company may be allowed to expand the current trial, the analyst adds. He sees the company's updates from Phase II melanoma, head and neck, and/or cervical studies in 2018 providing further share upside. Amin keeps a Buy rating on Iovance with a $31 price target.
03/13/18
RILY
03/13/18
NO CHANGE
Target $22
RILY
Neutral
Iovance price target raised to $22 from $18.50 at B. Riley FBR
B. Riley FBR analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $22 following the company's Q4 results. The analyst remains long-term positive on TIL technology in immuno-oncology, but says the absence of clinical catalysts and the stock's year-to-date share performance temper his enthusiasm near-term. He reiterates a Neutral rating on Iovance.

TODAY'S FREE FLY STORIES

02:10
09/21/18
09/21
02:10
09/21/18
02:10
General news
FX Action: USD-JPY has lifted to a fresh two-month high »

FX Action: USD-JPY has…

01:45
09/21/18
09/21
01:45
09/21/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap: Stock…

AYI

Acuity Brands

$161.46

3.9 (2.48%)

21:35
09/20/18
09/20
21:35
09/20/18
21:35
Upgrade
Acuity Brands rating change at Wells Fargo »

Acuity Brands upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

TTNP

Titan Pharmaceuticals

$0.50

-0.08 (-13.79%)

21:34
09/20/18
09/20
21:34
09/20/18
21:34
Syndicate
Titan Pharmaceuticals raises $9.5M in a public offering »

The securities offered by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MTEM

Molecular Templates

$5.81

-0.44 (-7.04%)

21:31
09/20/18
09/20
21:31
09/20/18
21:31
Syndicate
Molecular Templates 8.2M share Secondary priced at $5.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

YMAB

Y-mAbs Therapeutics

$0.00

(0.00%)

21:30
09/20/18
09/20
21:30
09/20/18
21:30
Syndicate
Y-mAbs Therapeutics 6M share IPO priced at $16.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

VKTX

Viking Therapeutics

$18.92

-0.72 (-3.67%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Viking Therapeutics 9.5M share Secondary priced at $18.50 »

William Blair, SunTrust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

  • 21

    Sep

TWIN

Twin Disc

$23.33

0.34 (1.48%)

21:28
09/20/18
09/20
21:28
09/20/18
21:28
Syndicate
Twin Disc 1.333M share Secondary priced at $22.50 »

Baird and Oppenheimer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

FTCH

Farfetch

$0.00

(0.00%)

21:26
09/20/18
09/20
21:26
09/20/18
21:26
Syndicate
Farfetch 44.244M share IPO priced at $20.00, above the range »

Goldman Sachs, JPMorgan,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

CRSP

Crispr Therapeutics

$48.90

-3 (-5.78%)

21:25
09/20/18
09/20
21:25
09/20/18
21:25
Syndicate
Crispr Therapeutics 4.211M share Secondary priced at $47.50 »

Goldman Sachs, Piper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 21

    Sep

MDCA

MDC Partners

$4.55

0.25 (5.81%)

21:08
09/20/18
09/20
21:08
09/20/18
21:08
Hot Stocks
MDC Partners to evaluate strategic alternatives »

MDC Partners announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWRE

Guidewire

$101.71

0.16 (0.16%)

20:27
09/20/18
09/20
20:27
09/20/18
20:27
Hot Stocks
Guidewire sees 5-year target revenue of about $1.3B »

Sees % subscription of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

AVMXY

Avita Medical

$0.00

(0.00%)

20:13
09/20/18
09/20
20:13
09/20/18
20:13
Hot Stocks
Avita Medical announces FDA approval of RECELL in burn treatment »

AVITA Medica announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.36

-0.03 (-1.26%)

20:05
09/20/18
09/20
20:05
09/20/18
20:05
Hot Stocks
Ladenburg Thalmann CEO to serve as chairman »

Ladenburg Thalmann…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

19:25
09/20/18
09/20
19:25
09/20/18
19:25
Conference/Events
Morgan Stanley multi-industrial analysts hold analyst/industry conference call »

U.S. Electrical Equipment…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

, SPX

S&P 500

$0.00

(0.00%)

19:15
09/20/18
09/20
19:15
09/20/18
19:15
General news
Trump's former lawyer Cohen met with Mueller multiple times, ABC says »

President Donald…

SPY

SPDR S&P 500 ETF Trust

$293.53

2.31 (0.79%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SCS

Steelcase

$16.10

0.8 (5.23%)

, ACAD

Acadia

$19.08

3.97 (26.27%)

19:09
09/20/18
09/20
19:09
09/20/18
19:09
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

SCS

Steelcase

$16.10

0.8 (5.23%)

ACAD

Acadia

$19.08

3.97 (26.27%)

TXN

Texas Instruments

$108.50

1.14 (1.06%)

MCD

McDonald's

$160.84

1.65 (1.04%)

RDS.A

Royal Dutch Shell

$66.83

0.57 (0.86%)

PIR

Pier 1 Imports

$1.80

0.045 (2.56%)

UNFI

United Natural Foods

$33.83

0.54 (1.62%)

MU

Micron

$46.06

1.01 (2.24%)

SGH

Smart Global

$30.44

0.7 (2.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 20

    Sep

  • 20

    Sep

  • 21

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 01

    Oct

  • 04

    Oct

  • 10

    Oct

  • 28

    Oct

KORS

Michael Kors

$72.72

-0.33 (-0.45%)

19:01
09/20/18
09/20
19:01
09/20/18
19:01
Hot Stocks
Michael Kors names Andrea Pesaresi head of Men's business »

Michael Kors Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

19:00
09/20/18
09/20
19:00
09/20/18
19:00
Hot Stocks
Medtronic to acquire Mazor Robotics for $58.50 per ADS, or about $1.64B »

Medtronic (MDT) and Mazor…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

MDT

Medtronic

$97.47

1.01 (1.05%)

, MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

18:59
09/20/18
09/20
18:59
09/20/18
18:59
Hot Stocks
Breaking Hot Stocks news story on Medtronic, Mazor Robotics »

Medtronic to acquire…

MDT

Medtronic

$97.47

1.01 (1.05%)

MZOR

Mazor Robotics

$52.70

2.44 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:54
09/20/18
09/20
18:54
09/20/18
18:54
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

ACAD

Acadia

$19.08

3.97 (26.27%)

18:48
09/20/18
09/20
18:48
09/20/18
18:48
Upgrade
Acadia rating change at Piper Jaffray »

Acadia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

SONA

Southern National Bancorp

$16.89

0.13 (0.78%)

18:45
09/20/18
09/20
18:45
09/20/18
18:45
Hot Stocks
Southern National Bancorp names Jeffrey Karafa CFO »

Southern National Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$298.32

-0.63 (-0.21%)

18:44
09/20/18
09/20
18:44
09/20/18
18:44
Periodicals
Tesla VP of global supply management O'Connor to leave company, Bloomberg says »

Liam O'Connor,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 26

    Sep

  • 29

    Oct

CRBP

Corbus Pharmaceuticals

$7.90

2.75 (53.40%)

18:34
09/20/18
09/20
18:34
09/20/18
18:34
Hot Stocks
Corbus CEO says wants to be leading pipeline for synthetic endocannabinoids »

Corbus Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 01

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.